Abstract:e21524 Background: The combination of anti-PD-1 plus axitinib as systemic therapy had promising antitumor activity in mucosal melanoma, but with limit effect in mucosal melanoma with liver metastasis, which might due to immunosuppression in liver metastasis. Oncolytic virus can heighten the immune response and turn over the immunosuppressive state, which has shown its efficacy in liver metastaic as Intra-hepatic injection. So we initiated this phase I study to evaluate axitinib combination with anti–PD-1 ab plus oncolytic virus in liver metastasis mucosal melanoma. Methods: Eligible pts included those over 18 years old, mucosal melanoma with injectable liver metastasis confirmed by biopsy with or without extra-hepatic metastasis. Pts received intravenous pucotenlimab Q3W combined plus axitinib 5 mg orally twice a day, combined with ultrasound guided intratumoral injection of OH2 Q2W (107CCID50/mL, 8ml per injection). Liver biopsy would be performed at first tumor evaluation (8-12weeks). The primary endpoint was ORR; secondary endpoints included toxicity, disease control rate (DCR), PFS and OS. Results: From Dec 2021 to Jan 2024, 20 pts were eligible and enrolled. Baseline characteristics: median age 56 yrs; 70% got previous treatment, (35% PD-1 resistant). 90% got extra-hepatic metastasis: regional or distant lymph node 45%, lung 40%,; LDH>ULN 50%; median size of target lesions: 61.5mm(12-155mm); median number of liver metastasis: 3(1-18) with median liver lesions 42.5mm(13-230mm). Till the last flow up, 15 pts were evaluable with a median follow-up of 9.39 months. The global ORR was 26.7% (4/15) with 42.9% lesionshrink, injection lesions decrease (43.8%) and non-injection lesion 23.1%. The DCR was 46.7% (7/15). There are still 8 pts on treatment at last follow up. The median PFS was 4.5m, and no pts who had response showed progression till last follow up, the mean DOR was 11.0m. Median OS is not reached. Biopsies of 13 pts for injected lesions at 8 to 12 weeks after first injection were examined to determine the situation of tumor regression and TIL infiltration. Among them, 3 pts (2 PD and 1 PR) had no melanoma cells residual by immunohistochemistry with impressive TIL infiltration. The biopsy showed better pathological response than radiological response which might explain some pts still got survival benefit on treatment after radiological PD. Most adverse events (AE) were grade 1-2 and manageable. Grade 3-4 treatment-related AE showed 30% pts, with diarrhea and oral ulceration as the most common. No treatment-related deaths occurred. Conclusions: Systemic anti-PD-1 plus axitinib combined intralesional injection of Oncolytic virus has shown preliminary efficacy in mucosal melanoma pts with liver metastases with manageable toxicity. Clinical trial information: NCT04206358 , NCT05070221 .

[Hepatic Intra-Arterial Bio-Chemotherapy for the Treatment of Melanoma Patients with Liver Metastasis: a Phase II Clinical Study].

The Phase 1 Clinical Trial of Anti–pd-1 (pucotenlimab) Plus Intrahepatic Injection of Oncolytic Virus (OH2) Combined with Radiotherapy of Liver Metastasis in Stage IV Melanoma.

Effect of Preoperative Hepatic and Regional Arterial Chemotherapy on Metachronous Liver Metastasis after Curative Colorectal Cancer Resection: A Prospective, Multicenter, Randomized Controlled Trial

A Pilot Study of Hepatic Arterial Infusion of Chemotherapy for Patients with Advanced Hepatocellular Carcinoma Who Have Failed Anti‐angiogenic Therapy

Malignant Melanoma Therapy by Chemotherapy and Autoimmunity Induced by Cytokine

Clinical results of treating metaphase and advanced hepatic carcinoma with intra-hepatic artery chemotherapy and embolizing therapy

Phase Ⅱ study of adoptive immunotherapy for advanced melanoma

Phase Ii Randomized Study of High-Dose Interferon Alfa-2b (hdi) Versus Chemotherapy As Adjuvant Therapy in Patients with Resected Mucosal Melanoma

Axitinib in Combination with Anti-Pd-1 Ab (pucotenlimab) Plus Intra-Hepatic Injection of Oncolytic Virus (OH2), in Patients with Mucosal Melanoma and Liver Metastasis: an Open-Label Phase I Trial

Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of orienX010 in stage IV melanoma with liver metastases.

Anti-Tumor Immune Response by Combining Cryoablation and Transarterial Infusion of Pembrolizumab (CATAP) for Liver Metastases of Melanoma

Chemocentric Chemoimmunotherapy: A New Concept in Melanoma Immunotherapy

Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients.

Chemotherapy for breast cancer progresses to liver metastases after surgery and systemic treatment

Clinical Evaluation of Targeted Arterial Infusion of Verapamil in the Interventional Chemotherapy of Primary Hepatocellular Carcinoma

Arterial Chemotherapy of 5-Fluorouracil and Mitomycin C in the Treatment of Liver Metastases of Colorectal Cancer

Hepatic Artery Injection of <SUP>131</SUP>I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial

Melphalan intra-arterial chemotherapy for choroidal melanoma chemoreduction

Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study

A retrospective clinical analysis of 30 cases of metastatic melanoma treated with first-line biochemotherapy

Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases from Colorectal Cancer: a Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481).